Long-lasting remission in a metastatic hepatocellular carcinoma patient after combined regorafenib therapy and surgery.

The therapeutic scenario of systemic treatments for hepatocellular carcinoma (HCC) is rapidly changing. There is much interest in the possibility of combining new therapies with surgery, but clinical data is lacking. We aimed to provide an example of such integration. We report a patient with metastatic HCC who received regorafenib in the setting of the RESORCE trial. A brilliant response led to a tumor downstaging and a subsequent adrenal metastasectomy with radical intent. New agents will change the therapeutic perspectives in advanced HCC and lead to a higher rate of objective responses, with possibilities of associating systemic therapy and surgery. Thus, the management of HCC will require more and more of an integrated, multidisciplinary and personalized approach.

© 2020 Francesco Tovoli.

Financial & competing interests disclosure  F Tovoli is a consultant for Bayer; E Goio, L Ielasi, F Benevento and M Renzulli have no conflicts of interest to declare. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.